BRAF and melanoma: In a recent paper on melanoma, tumor heterogeneity has been simulated in vivo by an admixture of 0.05% of A375 BRAF inhibitor-resistant melanoma cells to 99.95% of A375 BRAF inhibitor-sensitive melanoma cells [47].